中成药治疗心脏肥厚的临床相关结局比较:随机对照试验的系统评价与网络Meta分析
本研究通过系统评价与网络Meta分析,比较不同中成药联合西药治疗心脏肥厚的临床疗效与超声心动图指标。共纳入25项RCT、2395例患者,结果显示活血化瘀类中成药联合西药在临床疗效方面可能较优,益气活血化瘀类联合西药在降低左室收缩末期内径和左室质量指数方面可能最优。但因偏倚风险及RCT数量有限,结论需更大样本高质量研究验证。
要点
- 活血化瘀类中成药联合西药可能改善心脏肥厚患者临床疗效(OR=8.27)。
- 益气活血化瘀类中成药联合西药可能最优降低LVESD和LVMI。
- 证据受偏倚风险和RCT数量限制,需高质量大样本研究验证。
核心结论
- 活血化瘀类中成药联合西药可能是改善心脏肥厚患者临床疗效的潜在优势方案。
- 益气活血化瘀类中成药联合西药可能是降低左室收缩末期内径和左室质量指数的最佳治疗。
研究设计与样本
- 系统评价与网络Meta分析,纳入2012至2022年发表的25项随机对照试验,共2395例心脏肥厚患者。
- 检索四个外文数据库和四个中文数据库,采用Stata 16.0进行网络Meta分析。
主要发现
- 活血化瘀类中成药联合西药在临床疗效方面OR=8.27(95%CI=0.97, 70.73)。
- 益气活血化瘀类中成药联合西药降低LVESD的SMD=-2.35(95%CI=-3.09, -1.62),降低LVMI的SMD=-1.73(95%CI=-2.92, -0.54)。
- KWYR-CPM联合西药降低LVEDD的SMD=-1.84(95%CI=-3.46, -0.22);BASR-CPM改善LVEF的SMD=1.90(95%CI=-0.46, -3.35)。
关键数值与推荐
- 临床疗效评估采用比值比(OR)及95%可信区间。
- 超声心动图指标评估采用标准化均数差(SMD)及95%可信区间。
临床怎么用
- 对心脏肥厚患者,可考虑在西方医学治疗基础上联合活血化瘀类或益气活血化瘀类中成药以改善临床疗效或超声心动图指标。
- 具体中成药选择应结合患者临床特征及超声心动图表现,并关注证据局限性。
局限性
- 存在潜在偏倚风险。
- 纳入的随机对照试验数量有限。
- 需要更大样本和高质量随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Persistent pathological cardiac hypertrophy has been associated with increased risk of heart failure and even sudden death. Multiple Chinese patent medicines (CPMs) have gained attention as alternative and complementary remedies due to their high efficiency and few side effects. However, the effects of CPM-related treatment regimens for cardiac hypertrophy had not been systematically evaluated. Aim: The objective of this study was to estimate and compare the effectiveness of different mechanisms of CPMs to improve clinical outcomes, including clinical efficacy and echocardiographic indices, in the treatment of cardiac hypertrophy patents. Methods: A network meta-analysis was conducted on CPM-related randomized controlled trials (RCTs) published between 2012 and 2022 involving cardiac hypertrophy patients from four foreign and four Chinese databases. The outcomes concerned efficacy and related indicators, including echocardiographic indices, cardiac biomarkers, and functional exercise capacity, which were evaluated as odds ratios, mean differences, and 95% credible intervals. Network plots, league tables, surface-under-the-cumulative ranking (SUCRA), and funnel plots were created for each outcome, and all analyses were conducted using Stata 16.0 software. Results: A total of 25 RCTs were evaluated; these involved 2395 patients in a network meta-analysis (NMA). The results from existing evidence indicate that blood-activating and stasis-removing Chinese patent medicine (BASR-CPM) + Western medicine (WM) showed a good improvement in clinical efficacy (OR = 8.27; 95%CI = 0.97, 70.73). A combined treatment regimen of CPM with a function of qi-replenishing, blood-activating and stasis-removing, and Western medicine was an effective treatment regimen for echocardiographic indices such as decreasing left ventricular end-systolic dimension (LVESD) (SMD = -2.35; 95%CI = -3.09, -1.62) and left ventricular mass index (LVMI) (SMD = -1.73; 95%CI = -2.92, -0.54). Furthermore, KWYR-CPM + WM and BASR-CPM also showed good improvement for echocardiographic indices of LVEDD (SMD = -1.84; 95%CI = -3.46, -0.22) and left ventricular ejection fraction (SMD = 1.90; 95%CI = -0.46, -3.35), respectively. Conclusion: The study showed that BASR-CPM + WM may be the potentially superior treatment regimen for improving clinical efficacy among cardiac hypertrophy patients. QR&BASR-CPM + WM might be the optimal treatment for decreasing LVESD and LVMI. However, due to potential risks from bias and limited RCTs, further studies with larger samples and high-quality RCTs are needed to support these findings. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=329589],identifier [CRD42022329589].
引用
- Zhang T, Xu H, Zhen D, et al. Comparative clinical-related outcomes of Chinese patent medicines for cardiac hypertrophy: A systematic review and network meta-analysis of randomized clinical trials. Front Pharmacol. 2023. PMID: 36755943. doi:10.3389/fphar.2023.963099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。